×

INNATE PHARMA: New combination trial with lirilumab in hemato-oncology

  • 8 trials ongoing with lirilumab in multiple indications and combinations
  • 5 combination trials ongoing in hemato-oncology

MARSEILLE, France, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) announced that a new trial performed by the MD Anderson cancer center started, testing a combination of nivolumab, lirilumab and 5-azacytidine for the treatment of patients with Myelodysplastic Syndrome (MDS).

This is the third trial with lirilumab supported by Bristol-Myers Squibb and performed by the MD Anderson cancer center in 2015, after the opening of one trial testing the combination of lirilumab and 5-azacytidine in relapsed/ refractory AML and another trial testing the combination of lirilumab and rituximab in relapsed/ refractory or high-risk untreated CLL.

These new trials bring to 8 the number of trials performed with lirilumab, testing a broad range of solid and hematological cancer indications, multiple rationales and combinations with cytotoxic antibodies, checkpoint inhibitors and chemotherapy. See clinicaltrials.gov

About lirilumab (IPH2102/BMS-986015):

Lirilumab is a first-in-class checkpoint inhibitor, fully human monoclonal antibody (mAb) that blocks the interaction between Killer-cell immunoglobulin-like receptors (KIR) on NK cells and their ligands. Blocking these receptors facilitates activation of NK cells and destruction of tumor cells.

Lirilumab is licensed to Bristol-Myers Squibb Company. As part of the agreement between Innate Pharma and Bristol-Myers Squibb, Bristol-Myers Squibb holds exclusive worldwide rights to develop, manufacture and commercialize lirilumab and related compounds blocking KIR receptors, for all indications. Under the agreement, Innate Pharma conducts the development of lirilumab through Phase II in AML.

Innate is currently testing lirilumab in a randomized, double-blind, placebo-controlled Phase II trial as maintenance treatment in elderly patients with Acute Myeloid Leukemia ("AML") in first complete remission ("EffiKIR" trial). In addition, lirilumab is also being evaluated by Bristol-Myers Squibb in clinical trials in combination with other agents in a variety of tumor types.

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.

The Company has three clinical-stage programs, including two checkpoint inhibitors in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells.

Its innovative approach has translated into major alliances with leaders in the biopharmaceutical industry such as Novo Nordisk A/S, Bristol-Myers Squibb and AstraZeneca.

Listed on Euronext-Paris, Innate Pharma is based in Marseille, France, and had 112 employees at September 30, 2015.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code
Ticker code
FR0010331421
IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma ATCG Press
Laure-Hélène Mercier
Director, Investor Relations
Marie Puvieux (France)
Mob: +33 (0)6 10 54 36 72
Jean-Medhi Grangeon (ROW)
Tel.: +33 (0)4 30 30 30 87 Mob: +33 (0)6 62 22 00 24
investors@innate-pharma.com presse@atcg-partners.com

151112 IPH Update on lirilumab BMS http://hugin.info/155662/R/1966282/718044.pdf

HUG#1966282

Source: INNATE PHARMA